ESTRO 2024 - Abstract Book

S1951

Clinical - Mixed sites, palliation

ESTRO 2024

- Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A, et al. Surveillance or metastasis directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol 2018;36:446 – 53. https://doi.org/10.1200/JCO.2017.75.4853.

- Alongi F, Mazzola R, Ricchetti F. Consolidative local therapy in oligometastatic patients. Lancet Oncol 2017;18:. https://doi.org/10.1016/S1470-2045(17) 30014-1e60.

- de Vin T, Engels B, Gevaert T, Storme G, De Ridder M. Stereotactic radiotherapy for oligometastatic cancer: A prognostic model for survival. Ann Oncol 2014;25:467 – 71. https://doi.org/10.1093/annonc/mdt537.

- Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis- specific tool to estimate survival for patients with brain metastases. J Clin Oncol 2012;30:419 – 25. https://doi.org/10.1200/JCO.2011.38.0527.

1850

Digital Poster

Factors predict Complete Histological Response following neoadjuvant radiotherapy for rectal cancer

imane lahlali, karima nouni, fatimazahra babaouyoub, rachida laraichi, chadia ezzouitina, hanan elkacemi, tayeb kebdani, khalid hassouni

MOHAMMED V UNIVERSITY faculty of medicine and pharmacy of rabat, national institute of oncology department of radiotherapy, RABAT, Morocco

Purpose/Objective:

The current standard of care for locally advanced rectal cancer is radiotherapy combined with concurrent chemotherapy and surgery. This therapeutic approach enhances local control and raises the sphincter's rate of preservation. Additionally, in 20% of cases, a complete pathological response (pCR) might be obtained.

Our study's goal was to identify the factors that are predictive of p CR following a neoadjuvant RCT.

Material/Methods:

It is a retrospective study involving 430 patients with rectal cancer who were treated at Rabat's National Institute of Oncology between January 2018 and December 2022. They received concurrent Capecitabine-based chemotherapy and radiotherapy, as well as an ultimate surgical intervention.

Results: